| Address:
|
14282 FRANKLIN AVE
|
| City: |
TUSTIN |
|
State: |
CA |
|
Zip Code: |
92780 |
| Telephone: |
714-508-6000 |
|
Description of Business
|
Primary SIC Code:
2835 |
| (As filed with the SEC)
|
|
|
We are a clinical-stage biopharmaceutical company developing first-in-class
monoclonal antibodies for the treatment of cancer and viral infections. We are
advancing our two Phase II oncology platforms as well as our Phase I HCV
program. Our Phase II trials in lung, breast, and brain cancers have
demonstrated promising results, leading to two new randomized Phase II trials in
non-small cell lung cancer ("NSCLC").
Recently, we initiated the first of these trials, a randomized,
placebo-controlled, double-blinded Phase IIb trial evaluating bavituximab in
combination with standard chemotherapy in refractory NSCLC, which represents a
significant unmet medical need and potential fastest path to market. We have
also initiated recently the second trial, a randomized open-label Phase IIb
trial evaluating bavituximab in combination with chemotherapy in front-line
NSCLC. By the end of 2010, we plan to initiate another company-sponsored
trial. ... More ... |
| Date |
12-mos
Rolling EPS |
Dividend |
P/E
Ratio |
| 04/2010 | -0.30 | NA | N/E | | 01/2010 | -0.20 | NA | N/E | | 10/2009 | -0.25 | NA | N/E | | 07/2009 | -1.50 | NA | N/E |
Key Financial Ratios and Statistics |
FYE:
04/30 |
| Profitability |
2010 |
Leverage |
2010 |
| Net Inc/Comm Equity | -0.05 | Total Liab/Total Assets | 0.54 | | Net Inc/Total Assets | -0.49 | Total Liab/Inv Cap | 1.22 | | Net Inc/Inv Cap | -1.11 | Total Liab/Comm Equity | 0.06 | | Pretax Inc/Net Sales | -0.52 | Interest Coverage Ratio | -13.54 | | Net Inc/Net Sales | -0.52 | Curr Debt/Equity | 0.14 | | Cash Flow/Net Sales | -0.50 | LTD/Equity | 0.10 | | SG&A/NetSales | 0.29 | Total Debt/Equity | 0.24 |
| Asset Utilization
|
|
Liquidity |
|
| Net Receivables Turnover | 10.05 | Quick Ratio | 1.64 | | Inventory Turnover | 2.23 | Current Ratio | 1.86 | | Inventory Day Sales | 0.01 | Net Rec/Curr Assets | 0.07 | | Net Sales/Work Cap | 2.26 | Inv/Curr Assets | 0.12 | | Net Sales/PP&E | 19.02 | | |
Income Statement (Millions) |
| |
4/30/2010
|
1/31/2010
|
10/31/2009
|
7/31/2009
|
|
Total Revenues(Net Sales)
|
4.42
|
9.88
|
6.90
|
6.75
|
|
Cost of Goods Sold
|
2.23
|
1.87
|
3.54
|
1.07
|
|
Selling & Admin Exps
|
2.63
|
2.00
|
1.76
|
1.79
|
|
Operating Income
|
-7.57
|
-1.32
|
-2.54
|
-2.19
|
|
Interest Exp
|
0.19
|
0.24
|
0.28
|
0.28
|
|
Pretax Income
|
-7.74
|
-1.54
|
-2.79
|
-2.43
|
|
Other Income
|
0.02
|
0.02
|
0.03
|
0.04
|
|
Net Income Bef Extraordinary ...
|
NA
|
NA
|
NA
|
NA
|
|
Net Income
|
-7.74
|
-1.54
|
-2.79
|
-2.43
|
|
Assets
|
4/30/2010
|
1/31/2010
|
10/31/2009
|
7/31/2009
|
|
Cash & Short Term Investments
|
19.68
|
16.84
|
13.60
|
12.78
|
|
Receivables - Total
|
1.85
|
2.78
|
4.08
|
3.16
|
|
Inventories - Total
|
3.12
|
3.86
|
5.85
|
6.18
|
|
Total Current Assets
|
26.78
|
24.75
|
24.76
|
23.31
|
|
Net Property, Plant & Equipment
|
1.47
|
1.47
|
1.43
|
1.57
|
|
Total Assets
|
29.34
|
27.52
|
27.53
|
26.21
|
|
Liabilities
|
|
|
|
|
|
Accounts Payable
|
6.55
|
5.12
|
5.87
|
6.59
|
|
Debt in Current Liabilities
|
1.89
|
1.87
|
1.85
|
1.82
|
|
Total Current Liabilities
|
14.40
|
12.86
|
17.30
|
18.09
|
|
Long-Term Debt
|
1.32
|
1.80
|
2.16
|
2.74
|
|
Total Liabilities
|
15.93
|
14.88
|
19.61
|
20.99
|
|
Stockholder's Equity
|
|
|
|
|
|
Minority Interest
|
NA
|
NA
|
NA
|
NA
|
|
Preferred Stock
|
0.00
|
0.00
|
0.00
|
NA
|
|
Common Stock
|
0.05
|
0.05
|
0.05
|
0.24
|
|
Retained Earnings
|
-261.85
|
-254.11
|
-252.58
|
-249.79
|
|
Treasury Stock
|
NA
|
NA
|
NA
|
NA
|
|
Total Stockholders' Equity
|
13.41
|
12.65
|
7.92
|
5.23
|
|
Total Liabilities and Stockholders' Equity
|
29.34
|
27.52
|
27.53
|
26.21
|
Cash Flow Summary (Millions) |
|
Categories
|
4/30/2010
|
1/31/2010
|
10/31/2009
|
7/31/2009
|
|
Net Cash Provided by Operating Activities
|
-4.13
|
-2.34
|
-3.81
|
-3.59
|
|
Net Cash Provided by Investing Activities
|
-0.10
|
-0.14
|
-0.07
|
-0.06
|
|
Net Cash Provided by Financing Activities
|
7.07
|
5.71
|
4.70
|
6.42
|
Annual Summary Data (Millions) |
| Year |
Sales |
Net
Income |
EPS |
| 04/2006 | 3.19 | -17.06 | -- | | 04/2007 | 3.71 | -20.80 | -- | | 04/2008 | 6.09 | -23.18 | -- | | 04/2009 | 18.15 | -16.52 | -- | | 04/2010 | 27.94 | -14.49 | -0.30 | | Growth Rates | 72.00 | -- | -- |
| Type |
Date(Q,M) |
No.
Owners |
Shares
Held (000s) |
%
Own |
| Institutional | 06/30/10 | 62 | 8,019 | 14.56 |
|
Report Date :
8/30/2010
 Copyright
2010, EDGAR Online, Inc. All
rights reserved. Replication or redistribution of EDGAR Online, Inc. content is
expressly prohibited without the prior written consent of EDGAR Online, Inc.
EDGAR Online, Inc. shall not be liable for any errors or delays in the content,
or for any actions taken in reliance thereon.
|
|
|